CN107502650A - A kind of blood in vitro culture antineoplastic susceptibility detection method - Google Patents
A kind of blood in vitro culture antineoplastic susceptibility detection method Download PDFInfo
- Publication number
- CN107502650A CN107502650A CN201710987159.0A CN201710987159A CN107502650A CN 107502650 A CN107502650 A CN 107502650A CN 201710987159 A CN201710987159 A CN 201710987159A CN 107502650 A CN107502650 A CN 107502650A
- Authority
- CN
- China
- Prior art keywords
- blood
- cell
- antineoplastic
- culture
- detection method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
Abstract
The present invention discloses a kind of blood in vitro culture antineoplastic susceptibility detection method, belongs to biomedicine technical field, solves the problems, such as that existing susceptibility detects the tissue samples for needing biopsy or operation to obtain and can not carried out in tumour early stage, comprises the following steps：A) peripheral blood is gathered；B) tumour blood platelet, circulating tumor cell, the tumor stem cell in peripheral blood are separated；C) the tumour blood platelet isolated, circulating tumor cell, tumor stem cell are added into collagen and carries out 3 D stereo culture；D) medicine to be measured is added, is incubated in cell culture incubator；E) identification of form and growing state is carried out to cell using ATP TCA or MTT method, obtains susceptibility information of the tumour to antineoplastic.The present invention is to extract CTC, CSC and TEPs by whole blood to carry out determination of drug sensitivity, it is that a kind of tumour early the new approaches of sieve and drug sensitive experiment and has broad application prospects as to the biopsy of tumor patient blood and the target substance of medicaments insensitive Journal of Sex Research is carried out.
Description
Technical field
The present invention relates to biomedicine technical field, more particularly to a kind of blood in vitro culture antineoplastic susceptibility detection side
Method.
Background technology
The current incidence of tumour occupies the first in the world.Tumor patient medicine how is selected, carries out with a definite target in view accurate
The problem for the treatment of is current clinical staff concern.
Antineoplastic In vitro chemo-drug sensitive test can suggest that selection which or which medicine can be controlled accurately to medical personnel
Some individual tumors patient is treated, reaches the accurate treatment of chemotherapy of tumors medicine to avoid serious adverse reaction caused by chemotherapeutic.Mesh
The conventional sample standard deviation of the drug sensitive experiment of preceding antineoplastic is the tissue samples obtained by biopsy or operation.
Problems be present in existing antineoplastic susceptibility detection method：
1. the tissue samples still obtained whether through biopsy by performing the operation, can all cause a certain degree of wound to patient
Wound, inevitable pain can be not only caused to patient, is also unfavorable for the Health restoration of patient；
2. the tissue samples still obtained whether through biopsy by performing the operation, are required for tumor tissues to grow up to certain journey
Degree could be carried out, and can not be carried out in tumour early stage.
The content of the invention
To solve the deficiencies in the prior art, the present invention is intended to provide a kind of blood in vitro culture antineoplastic susceptibility detection side
Method, without obtaining tissue samples by operation, big wound will not be caused to patient；And it can be examined in tumour early stage
Survey.
To reach above-mentioned purpose, the technical solution adopted by the present invention is as follows：
A kind of blood in vitro culture antineoplastic susceptibility detection method disclosed by the invention, comprises the following steps：
A) peripheral blood is gathered；
B) tumour blood platelet, circulating tumor cell, the tumor stem cell in peripheral blood are separated；
C) the tumour blood platelet isolated, circulating tumor cell, tumor stem cell are added into collagen and carries out three-dimensional stand
Body culture；
D) medicine to be measured is added, is incubated in cell culture incubator；
E) identification of form and growing state is carried out to cell using ATP-TCA or MTT methods, obtains tumour to antitumor
The susceptibility information of medicine.
Hematological system is the important channel of metastases, and CTC (circulating tumor cell) and CSC is can detect in peripheral blood
(tumor stem cell) and TEPs (tumour blood platelet).Wherein CTC and CSC is respectively provided with powerful to tumour early sieve, medication and prognosis
Indicative function.Because the above two are extremely low in tumour early stage yield, blood platelet can because of the advantages that it measures big, easy enrichment in blood
As the prioritizing selection object for probing into tumour early screening and drug sensitive experiment technology.And according to known TEPs genes panel,
The detection of high accuracy can also be realized to early-stage cancer.Therefore, the present invention is to extract CTC, CSC and TEPs by whole blood to carry out medicine
Thing sensitivity testing, it is one as the target substance to the biopsy of tumor patient blood and progress medicaments insensitive Journal of Sex Research
Plant the new approaches of tumour morning sieve and drug sensitive experiment and have broad application prospects.
Preferably, after the c) step, primary screening is carried out：Cell in good condition is chosen, is collected by centrifugation, adds collagen
Albumen carries out 3 D stereo culture.Cell state after screening is good, and dead cell can be avoided to cause shadow to culture environment
Ring, so as to reduce interference, improve the accuracy of whole susceptibility detection.
Preferably, in the b) step, the tunica albuginea blood in peripheral blood is gathered first, then with tunica albuginea blood: Ficoll=2: 1
Ratio be added in the centrifuge tube containing Ficoll and centrifuge, suction out tunica albuginea with pasteur pipet, it is dilute with PBS (phosphate buffer)
Mixing washing is released, can conveniently be separated, and the cell of separation will not be damaged to, is advantageous to the growth of cell.
Further, after tunica albuginea PBS dilutes mixing washing, washed with basic culture solution, can further remove other
Impurity, and the cell isolated can be allowed to be relaxed, be advantageous to cell adapted follow-up culture environment.
Further, the condition of the 3 D stereo culture is：O2Content is 1%~18%, CO2Content be 1%~
10%, pressure is 1~4psi, and temperature is 25~40 DEG C, and humidity is 30%~95%.Found under this condition by many experiments
CTC, CSC and TEPs can well grow in collagen culture medium, the expansion of convenient detection.
Preferably, the condition of the 3 D stereo culture is：O2Content is 1%, CO2Content is 5%, pressure 2psi, temperature
Spend for 37~37.5 DEG C, humidity 95%.Closer to turning out CTC, CSC and TEPs its susceptibility for coming under human internal environment
The result of detection is more accurate, as a result more there is the meaning of clinical guidance.
Preferably, when adding collagen progress 3 D stereo culture, the cell density of cell suspension is thin for 2.5 × 105
Born of the same parents/ml.CTC, CSC and TEPs can well grow in collagen culture medium under the conditions of the cell density.
Further, in the d) step, the condition being incubated in cell culture incubator is：CO2Content is 5%, pressure 1
~4psi, temperature are 37 DEG C, humidity 95%, are cultivated 4 days.The incubation conditions simulate the environment in human body, being capable of analog drug
The mechanism of action of the thing in human body, the result for detecting susceptibility is more accurate, as a result more there is the meaning of clinical guidance.
Further, the d) step is carried out on 96 orifice plates, and a variety of medicines to be measured and the positive for adding various concentrations are right
According to medicine and blank control wells.Multigroup experiment, while the also convenient control group that not dosing is set can be carried out simultaneously using 96 orifice plates,
Can one-time detection multipacket message, the convenient drug reference information that most suitable patient is provided for medical personnel.
Preferably, in the e) step, the μ L of cell pyrolysis liquid 200 are separately added into each cell hole of 96 orifice plates, at room temperature
5min is mixed, 50uL mixing with cells solution is drawn respectively from each hole of 96 orifice plates and adds in luminous each hole of detection plate, successively each
The mixing of 50 μ L luciferase reagents is added in hole, with fluorescence detector fluorescence intensity, can obtain in each hole and cultivate carefully
The survival condition of born of the same parents, average value is calculated, obtain quantitative data and referred to for medical personnel.
The invention has the advantages that：
1. the present invention carries out the sensitivity Detection of chemotherapeutics using peripheral blood in patients, patient need not carry out biopsy or hand
Art, test samples source is simple, mitigates sampling pain of the tumor patient in the tumour diagnosis and treatment phase.
2. the susceptibility that the present invention in each neoplasm staging of illness can repeat in real time to tumor patient detects, and
When obtain newest optimal therapeutic scheme, the particularly examination to tumour early stage, can be as early as possible to patient carry out diagnoses and treatment,
In order to avoid delay treating time, the unnecessary cost of increase patient.
3. the present invention can realize accurately individuation, high efficiency using the blood of individual tumors patient as detection object
Antineoplaston scheme formulation, improve therapeutic effect while save medical resources.
4. the present invention has used develops more ripe detection mode now, high efficiency anti-tumor can be carried out to tumor patient
Drug susceptibility detects.
5. the present invention can provide accurate treatment of the optimal collocation realization of antineoplastic to tumour for clinic.
Embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, the present invention is carried out below further
Describe in detail.
Embodiment one：
To the patient of 75 patients with lung cancer and 25 non-malignant tumors, its peripheral blood 7.5mL is taken respectively, 4 degree preserve transport.
The tumour platelet rich in blood sample is branched away using immunomagnetic bead technique.Centrifugation 15 minutes, 2000rpm.It is dilute with PBS
Release mixing washing.Then continue to wash with basic culture solution.The collagen 3-dimensional stereoscopic culture prepared is added in washed cell
Liquid, then be transferred completely into blake bottle, put incubator overnight incubation.Condition when carrying out 3 D stereo culture is as follows：O2Content
In 1%, CO2Content is 5%, and pressure is in 2psi, and temperature is at 37 DEG C, and humidity is 95%.Next day adds medicine to be measured to each hole, often
Kind medicine sets 3 parallel holes, and sets not dosing control group.96 orifice plates are put into humidity and are more than 95%, 37 DEG C, 5%CO2, pressure
Power is incubated 4d in 1~4psi cell culture incubators.The μ L of cell pyrolysis liquid 200 are added in each cell hole of 96 orifice plates, are mixed at room temperature
5min, 50uL mixing with cells solution is drawn from each hole of 96 orifice plates and is added in luminous each hole of detection plate, is added successively in each hole
50 μ L luciferase reagents, mix.With fluorescence detector fluorescence intensity, average value is calculated.
Embodiment two：
Choose 120 patients with ovarian tumor, wherein oophoroma group 78.Borderline ovarian tumors group 42, the age 24~
72 years old, the median age 51 years old.Benign tumor of ovary group 50,18~71 years old age, the median age 49 years old.Choose with time health
Physical examination women 60 as a control group, 22~78 years old age, the median age 50 years old.Patient's early morning empty stomach venous blood samples 7.5mL
(take sample before without radiotherapy, chemotherapy or other treatment), is put into anticoagulant tube containing EDTA-K2 and fully mixes, after blood sampling in 2h
Platelet count is detected using XE-2000 whole blood cells automatic detection analysis instrument.Condition when carrying out 3 D stereo culture is as follows：
O2Content is in 1%, CO2Content is 5%, and pressure is in 2psi, and temperature is at 37.5 DEG C, and humidity is 60~95%.Next day adds to each hole
Medicine to be measured, every kind of medicine sets 3 parallel holes, and sets not dosing control group.96 orifice plates are put into 95%, 37 DEG C of humidity, 5%
CO2, pressure is incubated 4d in 2psi cell culture incubators.The μ L of cell pyrolysis liquid 200 are added in each cell hole of 96 orifice plates, are mixed at room temperature
5min is closed, 50uL mixing with cells solution is drawn from each hole of 96 orifice plates and is added in luminous each hole of detection plate, successively in each Kong Zhongjia
Enter 50 μ L luciferase reagents, mix.With fluorescence detector fluorescence intensity, average value is calculated.
Certainly, the present invention can also have other various embodiments, ripe in the case of without departing substantially from spirit of the invention and its essence
Various corresponding changes and deformation, but these corresponding changes and deformation can be made according to the present invention by knowing those skilled in the art
The protection domain of appended claims of the invention should all be belonged to.
Claims (10)
1. a kind of blood in vitro culture antineoplastic susceptibility detection method, it is characterised in that comprise the following steps：
A) peripheral blood is gathered；
B) tumour blood platelet, circulating tumor cell, the tumor stem cell in peripheral blood are separated；
C) the tumour blood platelet isolated, circulating tumor cell, tumor stem cell are added into collagen and carries out 3 D stereo training
Support；
D) medicine to be measured is added, is incubated in cell culture incubator；
E) identification of form and growing state is carried out to cell using ATP-TCA or MTT methods, obtains tumour to antineoplastic
Susceptibility information.
2. a kind of blood in vitro culture antineoplastic susceptibility detection method according to claim 1, it is characterised in that described
C) after step, primary screening is carried out：Cell in good condition is chosen, is collected by centrifugation, collagen is added and carries out 3 D stereo training
Support.
A kind of 3. blood in vitro culture antineoplastic susceptibility detection method according to claim 1 or 2, it is characterised in that
In the b) step, the tunica albuginea blood in peripheral blood is gathered first, then with tunica albuginea blood: Ficoll=2: 1 ratio, which is added to, to be contained
Have in Ficoll centrifuge tube and centrifuge, suction out tunica albuginea with pasteur pipet, diluted with PBS and mix washing.
A kind of 4. blood in vitro culture antineoplastic susceptibility detection method according to claim 3, it is characterised in that tunica albuginea
Diluted with PBS after mixing washing, washed with basic culture solution.
A kind of 5. blood in vitro culture antineoplastic susceptibility detection method according to claim 1 or 2, it is characterised in that
The condition of the 3 D stereo culture is：O2Content is 1%~18%, CO2Content is 1%~10%, and pressure is 1~4psi, temperature
Spend for 25~40 DEG C, humidity is 30%~95%.
6. a kind of blood in vitro culture antineoplastic susceptibility detection method according to claim 5, it is characterised in that described
The condition of 3 D stereo culture is：O2Content is 1%, CO2Content is 5%, pressure 2psi, and temperature is 37~37.5 DEG C, humidity
For 95%.
7. a kind of blood in vitro culture antineoplastic susceptibility detection method according to claim 5, it is characterised in that add
When collagen carries out 3 D stereo culture, the cell density of cell suspension is 2.5 × 105 cells/ml.
A kind of 8. blood in vitro culture antineoplastic susceptibility detection method according to claim 1 or 2, it is characterised in that
In the d) step, the condition being incubated in cell culture incubator is：CO2Content is 5%, and pressure is 1~4psi, temperature 37
DEG C, humidity 95%, cultivate 4 days.
9. a kind of blood in vitro culture antineoplastic susceptibility detection method according to claim 8, it is characterised in that described
D) step is carried out on 96 orifice plates, adds a variety of medicines to be measured and positive control drug and blank control wells of various concentrations.
A kind of 10. blood in vitro culture antineoplastic susceptibility detection method according to claim 9, it is characterised in that institute
State in e) step, the μ L of cell pyrolysis liquid 200 are separately added into each cell hole of 96 orifice plates, mix 5min at room temperature, from 96 orifice plates
50uL mixing with cells solution is drawn in each hole respectively to add in luminous each hole of detection plate, adds 50 μ L fluoresceins in each hole successively
Enzymatic reagent mixes, and with fluorescence detector fluorescence intensity, calculates average value.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710987159.0A CN107502650A (en) | 2017-10-20 | 2017-10-20 | A kind of blood in vitro culture antineoplastic susceptibility detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710987159.0A CN107502650A (en) | 2017-10-20 | 2017-10-20 | A kind of blood in vitro culture antineoplastic susceptibility detection method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107502650A true CN107502650A (en) | 2017-12-22 |
Family
ID=60701219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710987159.0A Pending CN107502650A (en) | 2017-10-20 | 2017-10-20 | A kind of blood in vitro culture antineoplastic susceptibility detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107502650A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108384836A (en) * | 2018-02-10 | 2018-08-10 | 四川省人民医院 | A kind of preclinical chemotherapeutics screening technique based on single-molecule DNA quantitative technique |
| WO2023209383A3 (en) * | 2022-04-27 | 2023-12-07 | Cancertain Limited | Method for predicting responsiveness to therapy |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104152410A (en) * | 2014-02-27 | 2014-11-19 | 赵树铭 | Method for inducing differentiation of umbilical cord blood stem cells to blood platelets by constructing three-dimensional (3D) culture system |
| CN104531620A (en) * | 2015-01-20 | 2015-04-22 | 天津医科大学肿瘤医院 | Method for culturing lung cancer stem cells under 3D culture conditions |
| CN106248922A (en) * | 2016-07-22 | 2016-12-21 | 嘉兴鼎诺生物科技有限公司 | A kind of drug sensitive test of tumor cell detection plate and detection method |
-
2017
- 2017-10-20 CN CN201710987159.0A patent/CN107502650A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104152410A (en) * | 2014-02-27 | 2014-11-19 | 赵树铭 | Method for inducing differentiation of umbilical cord blood stem cells to blood platelets by constructing three-dimensional (3D) culture system |
| CN104531620A (en) * | 2015-01-20 | 2015-04-22 | 天津医科大学肿瘤医院 | Method for culturing lung cancer stem cells under 3D culture conditions |
| CN106248922A (en) * | 2016-07-22 | 2016-12-21 | 嘉兴鼎诺生物科技有限公司 | A kind of drug sensitive test of tumor cell detection plate and detection method |
Non-Patent Citations (3)
| Title |
|---|
| 伍津津: "《皮肤组织工程学》", 30 June 2009 * |
| 闫国超等: "《肿瘤疾病临床检验与诊断》", 30 April 2017 * |
| 高春芳: "《实验室诊断新技术与临床》", 30 April 2010 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108384836A (en) * | 2018-02-10 | 2018-08-10 | 四川省人民医院 | A kind of preclinical chemotherapeutics screening technique based on single-molecule DNA quantitative technique |
| WO2023209383A3 (en) * | 2022-04-27 | 2023-12-07 | Cancertain Limited | Method for predicting responsiveness to therapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103940924B (en) | Cancer of the stomach gas mark in expiration is in the purposes prepared in stomach cancer diagnosis reagent | |
| CN104316685B (en) | Diacetyl spermine detection kit and preparation method and application thereof | |
| CN107502650A (en) | A kind of blood in vitro culture antineoplastic susceptibility detection method | |
| CN106367393A (en) | Mouse prostate cancer circulating tumor cell line and prostate cancer circulating tumor cell isolating and culturing method | |
| CN101446591A (en) | P16<INK4a> double antibody sandwich ELISA kit | |
| CN109355406B (en) | A kind of kit of the detection mycobacterium tuberculosis based on blood free nucleic acid | |
| CN101373188A (en) | Tumor-associated antigen 19-9 chemical luminescence immune analytic determination reagent kit and preparation method thereof | |
| CN109355261B (en) | Urinary bladder cancer cell culture medium and urinary bladder cancer cell in-vitro culture method | |
| CN116590377A (en) | Method for detecting sensitivity of patient-derived organ type tissue culture medicament | |
| CN114032277B (en) | Method for detecting drug sensitivity of tumor organoid based on staining method | |
| CN102435734A (en) | Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof | |
| CN105255986B (en) | A kind of preparation method of Armillaria luteo-virens fructification resisting liver cancer activity phytosterin compound | |
| CN110527726A (en) | The excretion body detection device and application for detecting for non-small cell lung cancer and judging by stages | |
| CN104974214B (en) | Jaligonic acid 30-methyl ester aminoguanidine derivatives Hu-17 and preparation method thereof | |
| CN106644903B (en) | It is present in brain source property particle in human peripheral venous blood and its separating-purifying identification method and application | |
| CN107012207A (en) | LRP5 is used as clinical diagnosis and the application of suppression digestive system tumor | |
| CN106350582A (en) | Serum miRNA marker related to auxiliary diagnosis for squamous lung cell carcinoma and application thereof | |
| CN106367477A (en) | Serum miRNA marker related to auxiliary diagnosis of colorectal cancer, and application thereof | |
| CN104897750B (en) | Circulating tumor cell detection probe and preparation method and application diagnostic sensor | |
| CN104655624A (en) | Preparation method of reagent for detecting monohydroxyphenyl metabolites in human saliva | |
| CN109745314A (en) | Application of the iron chelating agent Deferasirox (DFX) in the drug for the treatment of cervical carcinoma | |
| CN108277255A (en) | A kind of detection method of external activity epithelial tumor cell | |
| CN109342728A (en) | A kind of quality-control product being applicable in tumor markers Pro-GRP quantitative detection | |
| Mendonça et al. | FREQUENCY AND ANALYSIS OF THE EPIDEMIOLOGICAL PROFILE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN PATIENTS FROM A BRAZILIAN DIAGNOSTIC CENTER | |
| CN104974985A (en) | Method of quickly separating breast cancer primary tumor living cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171222 |
|
| RJ01 | Rejection of invention patent application after publication |